InsiderTrades.com logo
New crypto project uncovers 2,050% in 65 days
From InvestorPlace   |   Ad
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Just click here to sign up and be among the first to get it.
Sriram Sathyanarayanan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Sriram Sathyanarayanan Biography and Net Worth

Insider of Codiak BioSciences
Prior to being named Chief Scientific Officer at Codiak, Dr. Sathyanarayanan was Senior Vice President, Preclinical Development. In this role, he designed and led the preclinical evaluation of all of Codiak’s development programs in oncology/immuno-oncology, including exoIL-12™ and exoSTING™, and exoASO™-STAT6. Dr. Sathyanarayanan joined Codiak in 2017 as Vice President, Biology and Translational Sciences after spending four years developing biomarker strategies to enable clinical development of novel cancer immunotherapy agents, including JTX-2011 from inception to Phase 2 clinical development, at Jounce Therapeutics as Senior Director, Translational Sciences. He began his career in drug discovery at Merck Research Laboratories where he was responsible for building translational oncology strategy for multiple biologics and small molecule programs including Dalotuzumab and Ridaforolimus. Dr. Sathyanarayanan completed his post-doctoral research at the University of Pennsylvania School of Medicine. He received his Ph.D. in microbiology and cell biology from the Indian Institute of Science and masters and undergraduate degrees in biochemistry from PSG College.

What is Sriram Sathyanarayanan's net worth?

The estimated net worth of Sriram Sathyanarayanan is at least $2.80 as of January 20th, 2023. Dr. Sathyanarayanan owns 1,752 shares of Codiak BioSciences stock worth more than $3 as of April 19th. This net worth approximation does not reflect any other assets that Dr. Sathyanarayanan may own. Additionally, Dr. Sathyanarayanan receives an annual salary of $502,170.00 as Insider at Codiak BioSciences. Learn More about Sriram Sathyanarayanan's net worth.

How old is Sriram Sathyanarayanan?

Dr. Sathyanarayanan is currently 50 years old. There are 6 older executives and no younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences is Dr. Douglas Edward Williams Ph.D., Pres, CEO & Director, who is 64 years old. Learn More on Sriram Sathyanarayanan's age.

What is Sriram Sathyanarayanan's salary?

As the Insider of Codiak BioSciences, Inc., Dr. Sathyanarayanan earns $502,170.00 per year. There are 2 executives that earn more than Dr. Sathyanarayanan. The highest earning executive at Codiak BioSciences is Dr. Douglas Edward Williams Ph.D., Pres, CEO & Director, who commands a salary of $970,770.00 per year. Learn More on Sriram Sathyanarayanan's salary.

How do I contact Sriram Sathyanarayanan?

The corporate mailing address for Dr. Sathyanarayanan and other Codiak BioSciences executives is , , . Codiak BioSciences can also be reached via phone at 617-949-4100 and via email at [email protected]. Learn More on Sriram Sathyanarayanan's contact information.

Has Sriram Sathyanarayanan been buying or selling shares of Codiak BioSciences?

Sriram Sathyanarayanan has not been actively trading shares of Codiak BioSciences within the last three months. Most recently, Sriram Sathyanarayanan sold 1,082 shares of the business's stock in a transaction on Friday, January 20th. The shares were sold at an average price of $0.58, for a transaction totalling $627.56. Following the completion of the sale, the insider now directly owns 1,752 shares of the company's stock, valued at $1,016.16. Learn More on Sriram Sathyanarayanan's trading history.

Who are Codiak BioSciences' active insiders?

Codiak BioSciences' insider roster includes Nicole Barna (Insider), Konstantin Konstantinov (CTO), Sriram Sathyanarayanan (Insider), and Benny Sorensen (Insider). Learn More on Codiak BioSciences' active insiders.

Sriram Sathyanarayanan Insider Trading History at Codiak BioSciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/20/2023Sell1,082$0.58$627.561,752View SEC Filing Icon  
8/9/2021Sell1,300$21.51$27,963.00View SEC Filing Icon  
8/9/2021Sell1,300$21.51$27,963.00View SEC Filing Icon  
8/6/2021Sell1,300$20.16$26,208.00View SEC Filing Icon  
See Full Table

Sriram Sathyanarayanan Buying and Selling Activity at Codiak BioSciences

This chart shows Sriram Sathyanarayanan's buying and selling at Codiak BioSciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codiak BioSciences Company Overview

Codiak BioSciences logo
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00
Low: $0.05
High: $6.98

Volume

N/A

Average Volume

1,366,845 shs

Market Capitalization

$58,928.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.71
AI “wealth window” is closing soon!
From Paradigm Press   |   Ad
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
I put together this personal video [HERE]…